Aditxt (ADTX) Cash from Financing Activities (2019 - 2026)
Aditxt (ADTX) recorded quarterly Cash from Financing Activities of $1.7 million in Q1 2026, down 86.5% quarter-over-quarter from $12.3 million in Q4 2025, and down 85.39% on a YoY basis from $11.4 million in Q1 2025.
Aditxt (ADTX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Aditxt's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 85.39% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $20.8 million (down 25.47% YoY), while the FY2025 annual figure was $30.5 million, up 35.53% from the prior year.
- Cash from Financing Activities was $1.7 million for Q1 2026 at Aditxt, down from $12.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $16.2 million in Q3 2022 to a low of -$184184.0 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $5.2 million across 5 years, with a median of $3.3 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities plunged 102.28% in 2022, then jumped 3620.97% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at $64012.0 in 2022, then surged by 3620.97% to $2.4 million in 2023, then surged by 294.29% to $9.4 million in 2024, then surged by 30.92% to $12.3 million in 2025, then sank by 86.5% to $1.7 million in 2026.
- The last three Cash from Financing Activities figures came in at $1.7 million (Q1 2026), $12.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Aditxt | 2,485.68 | -2.16 Mn | 2,868.00 | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.66 Mn |
| Dec 31, 2025 | 12.29 Mn |
| Dec 31, 2025 | 12.29 Mn |
| Sep 30, 2025 | 2.18 Mn |
| Sep 30, 2025 | 2.18 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | 11.36 Mn |
| Mar 31, 2025 | 11.36 Mn |
| Dec 31, 2024 | 9.39 Mn |
| Dec 31, 2024 | 9.39 Mn |
| Sep 30, 2024 | 3.86 Mn |
| Sep 30, 2024 | 3.86 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Mar 31, 2024 | 5.95 Mn |
| Mar 31, 2024 | 5.95 Mn |
| Dec 31, 2023 | 2.38 Mn |
| Dec 31, 2023 | 2.38 Mn |